INTS•prnewswire•
Intensity Therapeutics Highlights 2025 Milestones and Outlines 2026 Strategic Priorities
Summary
Peer-reviewed clinical validation, strengthened balance sheet, and disciplined execution position the Company for 2026 SHELTON, Conn., Jan. 13, 2026 /PRNewswire/ -- Intensity Therapeutics, Inc. (Nasdaq: INTS) ("Intensity" or "the Company"), a late-stage clinical biotechnology company...
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on January 13, 2026 by prnewswire